文献速递乳腺MR

治疗后MRI预测三阴性乳腺癌新辅助化疗免疫治疗病理完全缓解

Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy.
PubMed 文献 · Radiology · 2025-01-01

这项前瞻性多中心研究评估治疗后MRI预测早期三阴性乳腺癌新辅助化疗免疫治疗后病理完全缓解的性能。放射学完全缓解(肿瘤床无强化)预测病理完全缓解的AUC为0.83,联合模型(放射学完全缓解+淋巴结状态+Ki-67)在外部测试集AUC为0.88。在放射学完全缓解的非病理完全缓解病例中,残余癌负荷均限于I级。

要点

  • 治疗后MRI显示肿瘤床无强化(放射学完全缓解)对病理完全缓解有较强预测价值,测试集AUC为0.88(联合模型)。
  • 淋巴结阴性且Ki-67大于30%的患者中,放射学完全缓解的假发现率训练集为3.6%(2/56),测试集为3.5%(1/29)。
  • 非放射学完全缓解病例中,结合影像组学评分和病灶计数的模型AUC为0.80(95%CI:0.69,0.90)。

核心结论

  • 治疗后MRI的放射学完全缓解对早期三阴性乳腺癌新辅助化疗免疫治疗后的病理完全缓解显示出较强预测价值。

研究设计与样本

  • 前瞻性多中心研究,2021年8月至2024年6月,从三个中心招募早期三阴性乳腺癌女性,训练集175例(平均年龄49岁±11),外部测试集84例(平均年龄52岁±12)。
  • 分析来自多个厂商的治疗后动态对比增强MRI扫描,评估放射学完全缓解(肿瘤床无强化)预测病理完全缓解。
  • 开发并外部验证了包含放射学完全缓解、淋巴结受累和Ki-67指数的多变量逻辑回归模型。
  • 在残余强化(非放射学完全缓解)病例中,测试了使用形状和一阶特征的影像组学评分。

诊断标准与关键数值

  • 放射学完全缓解定义为肿瘤床无强化。
  • 放射学完全缓解预测病理完全缓解的AUC为0.83(95%CI:0.75,0.92)。
  • 联合模型(放射学完全缓解+淋巴结状态+Ki-67)在测试集AUC为0.88(95%CI:0.81,0.96)。
  • 淋巴结阴性且Ki-67大于30%的患者中,放射学完全缓解的假发现率训练集为3.6%(2/56),测试集为3.5%(1/29),所有癌症残余癌负荷均限于I级。
  • 非放射学完全缓解病例中,结合影像组学评分和病灶计数的模型AUC为0.80(95%CI:0.69,0.90)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Neoadjuvant chemoimmunotherapy (NACI) has substantially improved pathologic complete response (pCR) rates in early triple-negative breast cancer (TNBC). However, the predictive accuracy of posttreatment MRI remains unexplored. Purpose To assess the performance of posttreatment MRI in the prediction of pCR in participants with TNBC treated with NACI. Materials and Methods In this prospective multicenter study (August 2021-June 2024), women with early TNBC were recruited from three centers (training set: Institut Curie; test set: Institut Godinot and Institut Oscar Lambret). Post-NACI dynamic contrast-enhanced MRI scans from multiple vendors were analyzed. Radiologic complete response (rCR)-defined as no enhancement in the tumor bed-was evaluated for predicting pCR. A multivariable logistic regression model incorporating rCR, nodal involvement, and Ki-67 index was developed and externally validated. In cases with residual enhancement (non-rCR), a radiomic score using shape and first-order features was tested. Results A total of 175 women were included in the training set (mean age, 49 years ± 11 [SD]) and 84 women in the external test set (mean age, 52 years ± 12). The rCR at MRI was predictive of pCR, with an area under the receiver operating characteristic curve (AUC) of 0.83 (95% CI: 0.75, 0.92). The combined model (rCR + nodal status + Ki-67) yielded an AUC of 0.88 (95% CI: 0.81, 0.96) in the test set. In node-negative patients with Ki-67 greater than 30%, the rCR false-discovery rate (ie, the proportion of rCR cases that were actually non-pCR or residual disease missed at breast MRI) was 3.6% (two of 56) in the training set and 3.5% (one of 29) in the test set; all cancers were limited to residual cancer burden I. In non-rCR cases, a model incorporating the radiomics score and lesion count achieved an AUC of 0.80 (95% CI: 0.69, 0.90). Conclusion Posttreatment rCR at MRI demonstrated strong predictive value for pCR in early TNBC following NACI. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Onishi in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Ramtohul T, Lollivier D, Spriet J, et al. Posttreatment MRI to Predict Pathologic Complete Response of Triple-Negative Breast Cancer to Neoadjuvant Chemoimmunotherapy. Radiology. 2025. PMID: 40590696. doi:10.1148/radiol.243824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。